The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open label, single arm phase II, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16- or 18-positive cervical cancer and failure of first-line platinum-based chemotherapy (DURBAC).
 
Chel Hun Choi
No Relationships to Disclose
 
Byoung-Gie Kim
No Relationships to Disclose
 
Jeong-Won Lee
No Relationships to Disclose
 
Tae-Joong Kim
No Relationships to Disclose
 
Yoo-Young Lee
No Relationships to Disclose
 
Duck Cho
No Relationships to Disclose
 
Byoung-Kwan Hun Park
No Relationships to Disclose
 
Sang Yong Song
No Relationships to Disclose
 
Dae-Yeon Kim
No Relationships to Disclose
 
Kidong Kim
No Relationships to Disclose
 
Hee Seung Kim
No Relationships to Disclose
 
Jung-Yun Lee
No Relationships to Disclose
 
Myong Cheol Lim
Consulting or Advisory Role - AstraZeneca; Boryung; CKD Pharm; Genexine; GI Innovation; Hospicare; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma; AstraZeneca (Inst); BeiGene (Inst); Cellid (Inst); CKD pharm (Inst); Clovis Oncology (Inst); Eisai (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); MSD (Inst); OncoQuest (Inst); Pfizer (Inst); Roche (Inst)
 
Insu Jeon
No Relationships to Disclose
 
By-yeong Song
No Relationships to Disclose
 
Kwang-Soo Shin
No Relationships to Disclose
 
Wuhyun Kim
No Relationships to Disclose
 
Chang-Yuil Kang
No Relationships to Disclose